

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claims 1-16 (Canceled).

Claim 17 (Currently Amended): ~~A~~An isolated nucleic acid molecule encoding ~~the a~~  
fusion protein of ~~claim 1~~comprising the amino acid sequence of SEQ ID NO: 1.

Claim 18 (Currently Amended): ~~A~~An isolated vector ~~containing~~comprising the  
nucleic acid molecule of claim 17.

Claim 19 (Currently Amended): The isolated vector of claim 18, wherein said vector  
is ~~derived from one or more a~~ bacterial plasmid~~plasmid, bacteriophages a bacteriophage~~  
vector, yeast episomes a yeast episomal vector, artificial chromosomes an artificial  
chromosomal vector, or from viruses a viral vector, selected from the group consisting of  
baculoviruses, papovaviruses, herpes viruses, adenoviruses, adenovirus-associated viruses  
(AAV), poxviruses, foamy viruses, and retroviruses.

Claim 20 (Currently Amended): The isolated vector of ~~claim 19~~claim 55, wherein  
said vector is an adenoviral vector.

Claim 21 (Currently Amended): The isolated vector of claim 20, wherein said vector  
is an E1- and E3-deleted replication-defective adenoviral vector comprising the nucleic acid  
molecule ~~according to~~of claim 17 inserted in replacement of the E1 region and placed under  
the control of the CMV promoter.

Claim 22 (Currently Amended): The isolated vector of claim 18, wherein said vector  
further comprises one or more transgenes encoding (i) a tumor proliferation inhibitor and/or  
(ii) at least one antigen ~~against which an immune response is desired.~~

Claim 23 (Currently Amended): The isolated vector of claim 22, wherein said tumor proliferation inhibitor is a fusion protein which encodes a two domain enzyme possessing both CDase and UPRTase activities.

Claim 24 (Currently Amended): The isolated vector of claim 22, wherein said ~~specific~~ antigen is a HPV antigen selected from the group consisting of E5, E6, E7, L1, and L2 either individually or in combination.

Claim 25 (Currently Amended): The isolated vector of claim 24, wherein said HPV antigen is a membrane-anchored form of a non-oncogenic variant of the early HPV-16 E6 and/or E7 antigen.

Claim 26 (Withdrawn-Currently Amended): An isolated infectious viral particle comprising ~~a~~ the nucleic acid molecule ~~according to~~ of claim 17.

Claim 27 (Withdrawn-Currently Amended): A process for producing an infectious viral particle comprising the nucleic acid molecule of claim 17, comprising the steps of :

- (a) introducing the viral vector of ~~claim 18~~ claim 54 into a suitable cell line,
- (b) culturing said cell line under suitable conditions so as to allow the production of said infectious viral particle, and
- (c) recovering the produced infectious viral particle from the culture of said cell line, and
- (d) optionally purifying said recovered infectious viral particle.

Claim 28 (Currently Amended): ~~A~~ An isolated host cell comprising the nucleic acid molecule ~~according to~~ of claim 17.

Claim 29 (Currently Amended): A method for producing a fusion protein, comprising the steps of:

- (a) introducing a ~~the~~ vector ~~according to~~ of claim 18 into a suitable host cell to produce a transfected or infected host cell,

(b) culturing *in-vitro* said transfected or infected host cell under conditions suitable for growth of the host cell, and

(c) ~~thereafter~~ recovering said fusion protein from said ~~the~~ culture of said host cell, and

(d) optionally, purifying said recovered fusion protein.

Claim 30-41: (Canceled).

Claim 42 (Withdrawn-Currently Amended): An isolated infectious viral particle comprising ~~at the~~ vector ~~according to~~ of claim 18.

Claim 43 (Withdrawn-Currently Amended): ~~A~~ An isolated host cell comprising the vector of ~~claim 26~~ claim 18.

Claim 44 (Withdrawn-Currently Amended): ~~A~~ An isolated host cell comprising the infectious viral particle of claim 26.

Claim 45 (Currently Amended): A ~~pharmaceutical~~ composition comprising ~~an effective amount of the vector according to~~ of claim 18 and a pharmaceutically acceptable vehicle.

Claim 46 (Withdrawn-Currently Amended): A ~~pharmaceutical~~ composition comprising ~~an effective amount of the infectious viral particle according to~~ of claim 26 and a pharmaceutically acceptable vehicle.

Claim 47 (Currently Amended): A ~~pharmaceutical~~ composition comprising ~~an effective amount of the host cell according to~~ of claim 28 and a pharmaceutically acceptable vehicle.

Claim 48-53 (Previously Presented): (Canceled).

Claim 54 (New): The isolated vector of claim 19, wherein said vector is a viral vector.

Claim 55 (New): The isolated vector of claim 54, wherein said viral vector is selected from the group consisting of baculoviral vectors, papoviral vectors, herpes viral vectors, adenoviral vectors, adenovirus-associated viral vectors, poxviral vectors, foamy viral vectors, and retroviral vectors.